Rheumatology

ABP 501 is an adalimumab biosimilar that was recently approved the European Medicines Agency.

Data from a phase 2 trial presented at ACR Convergence 2022 provides clinicians with insight into the effects of deucravacitinib, a TYK2 inhibitor, in patient populations with systemic lupus erythematosus.

The results show 88.1% of patients with rheumatoid arthritis in the study developed humoral immunogenicity.

Investigators used interviews, performed in a patient’s preferred language and transcribed verbatim, to better uncover and understand what matters most to the Hispanic population.

A post hoc subgroup analysis compared TNFi-IR patients receiving upadacitinib 15 mg once daily in 3 Phase 3 clinical trials: SELECT-BEOYND, SELECT-CHOICE, and SELECT-COMPARE.

A systematic review and meta-analysis presented at ACR Convergence 22 provide insight into the effects of belimumab in patient populations with cutaneous lupus erythematosus, with or without systemic lupus erythematosus.

There was also a reduction in ultrasound features of gout at the knee identified, with improvement found in 63% of the tight control group and 14% of the conventional group.

“It’s very possible to reach the Hispanic community and to go above and beyond what is currently being done, which is very little in terms of supporting them and giving them the tools that they need to create to have a better quality of life."

There were no significant safety issues in the group of patients treated with secukinumab for more than 3 years.

Exposure to more than 100 mg was linked to significantly lower odds ratios for first-ever ACS event for women.

Gout, if left untreated, can lead to flares that can increase the likelihood of depression and anxiety.

The results also show substantial medication substitution across prescription drug classes related to medical cannabis use.

Low levels of disease activity were achieved and increased throughout the study.

Data from the CONSUL trial provide insight into the effects of TNF inhibitor monotherapy compared against combination therapy with NSAIDs for blunting radiographic spinal progression in adults with radiographic axial spondyloarthritis.

The median time-to-remission was longer for women compared to men.

Wipfler emphasized that most of the delays have been associated with pharmacies needing to confirm the purpose of the prescription with the provider.

A significantly larger portion of patients in the telitacicept 160 mg achieved SR14 response compared to the placebo group.

An analysis of more than 17,000 Veterans suggests early initiation of TNF inhibitor therapy in patients with ankylosing spondylitis was associated with an increased risk of incident cardiovascular disease and major adverse cardiovascular events.

“We imagine that the rate of problems [accessing methotrexate] is going to be much higher in higher-risk populations," Wipfler explained.

Individuals who were socially isolated at time of fracture had significantly worse function, ability to participate in social roles, and depression time of fracture.

Hamilton and his team aim to reduce intensive and often unnecessary screening, including weekly fetal cardiac ultrasounds, via autoantibody identification.

Anti-osteoporotic treatment resulted in increased BMD to a greater extent in patients treated with less than 5 mg per day of prednisone.

The number of autoantibodies and congenital heart block pregnancies expanded to approximately 30 different autoantibodies to different targets near term.

The results show improvements in RAPID3, pain, fatigue, and morning stiffness at weeks 8 and 12 among patients treated with upadacitinib.

Cuoghi Camille Edens, MD, discusses her upcoming ACR presentation, “Fertility and the Use of Assisted Reproductive Technologies: Perceptions, Thoughts and Experiences of Men and Women with Rheumatic Disease.”

Patients with ankylosing spondylitis generally had more favorable outcomes compared to those with psoriasis or psoriatic arthritis.

Although patients with autoimmune diseases are more likely to develop severe vaccine-preventable infections, vaccine uptake remains relatively low in this patient population.

In data presented during ACR, investigators find peresolimab could be an effective treatment for adult patients with rheumatoid arthritis.

EULAR guidelines suggest that non-pharmacological therapies should be prioritized over treatment with medication.

Investigators believe it is important to understand the patient's perspective regarding vaccine concerns and combining that perspective with stakeholders to prioritize topics for future research.